ACS chemical neuroscience molecule spotlight on Sabril

ACS Chem Neurosci. 2010 Jul 21;1(7):475. doi: 10.1021/cn100025k.

Abstract

Sabril (vigabatrin) oral solution was approved by the FDA on August 21st, 2009 for treatment of infantile spasms in children ages 1 month to 2 years and complex partial seizures in adults (tablets).

Publication types

  • Review

MeSH terms

  • 4-Aminobutyrate Transaminase / antagonists & inhibitors
  • Anticonvulsants / adverse effects
  • Anticonvulsants / chemistry*
  • Anticonvulsants / pharmacology
  • Anticonvulsants / therapeutic use
  • Clinical Trials as Topic
  • Double-Blind Method
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Epilepsy / drug therapy
  • Epilepsy / enzymology
  • Humans
  • Molecular Structure
  • Multicenter Studies as Topic
  • Randomized Controlled Trials as Topic
  • Single-Blind Method
  • Vigabatrin / adverse effects
  • Vigabatrin / chemistry*
  • Vigabatrin / pharmacology
  • Vigabatrin / therapeutic use
  • Vision Disorders / chemically induced

Substances

  • Anticonvulsants
  • Enzyme Inhibitors
  • 4-Aminobutyrate Transaminase
  • Vigabatrin